Volgen
Linda E. Klumpers
Linda E. Klumpers
Clinical Scientist
Geverifieerd e-mailadres voor chdr.nl
Titel
Geciteerd door
Geciteerd door
Jaar
Brief treatment with the glucocorticoid receptor antagonist mifepristone normalises the corticosterone‐induced reduction of adult hippocampal neurogenesis
JL Mayer, L Klumpers, S Maslam, ER De Kloet, M Joels, PJ Lucassen
Journal of neuroendocrinology 18 (8), 629-631, 2006
2262006
A brief background on cannabis: From plant to medical indications
LE Klumpers, DL Thacker
Journal of AOAC International 102 (2), 412-420, 2019
1252019
Manipulating brain connectivity with δ9-tetrahydrocannabinol: a pharmacological resting state FMRI study
LE Klumpers, DM Cole, N Khalili-Mahani, RP Soeter, ET Te Beek, ...
Neuroimage 63 (3), 1701-1711, 2012
1152012
Novel Δ9‐tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects
LE Klumpers, TL Beumer, JGC van Hasselt, A Lipplaa, LB Karger, ...
British journal of clinical pharmacology 74 (1), 42-53, 2012
902012
Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short-and long-term pharmacokinetics
JAAC Heuberger, Z Guan, OO Oyetayo, L Klumpers, PD Morrison, ...
Clinical pharmacokinetics 54, 209-219, 2015
862015
Peripheral selectivity of the novel cannabinoid receptor antagonist TM 38837 in healthy subjects
LE Klumpers, M Fridberg, ML de Kam, PB Little, NO Jensen, HD Kleinloog, ...
British Journal of Clinical Pharmacology 76 (6), 846-857, 2013
772013
Review of delta‐8‐tetrahydrocannabinol (Δ8‐THC): Comparative pharmacology with Δ9‐THC
M Tagen, LE Klumpers
British journal of pharmacology 179 (15), 3915-3933, 2022
682022
Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9‐tetrahydrocannabinol‐induced central nervous system and heart rate effects in humans
LE Klumpers, C Roy, G Ferron, S Turpault, F Poitiers, JL Pinquier, ...
British Journal of Clinical Pharmacology 76 (1), 65-77, 2013
312013
Subjective Effects of Ethanol, Morphine, Δ9-Tetrahydrocannabinol, and Ketamine Following a Pharmacological Challenge Are Related to Functional Brain Connectivity
D Kleinloog, S Rombouts, R Zoethout, L Klumpers, M Niesters, ...
Brain connectivity 5 (10), 641-648, 2015
152015
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease
M Tagen, D Mantuani, L van Heerden, A Holstein, LE Klumpers, ...
Journal of Psychopharmacology 37 (9), 876-890, 2023
62023
Surinabant, a selective CB (1) antagonist, inhibits THC-induced central nervous system and heart rate effects in humans
LE Klumpers, C Roy, G Ferron, S Turpault, F Poitiers, JL Pinquier, ...
Br J Clin Pharmacol 76, 65-77, 2013
52013
Pharmacokinetic/pharmaco–dynamic modelling and simulation of the effects of different cannabinoid receptor type 1 antagonists on Δ9‐tetrahydrocannabinol …
Z Guan, LE Klumpers, OO Oyetayo, J Heuberger, JMA van Gerven, ...
British Journal of Clinical Pharmacology 81 (4), 713-723, 2016
32016
304 Randomized Controlled Trial of ANEB-001 as an Antidote for Acute Cannabinoid Intoxication in Healthy Adults
A Monte, A Gorbenko, J Heuberger, KC Cundy, L Klumpers, ...
Annals of Emergency Medicine 82 (4), S133, 2023
12023
Fall 2020 proceedings of the cannabis chemistry subdivision
NB Arora, JL von Salm
ACS Chemical Health & Safety 28 (2), 73-93, 2021
12021
Novel approaches in clinical development of cannabinoid drugs
L Klumpers
Br J Clin Pharmacol 76 (1), 65-77, 2013
12013
First in human trial of an oral tablet with Delta 9-THC (Namisol (R))
LE Klumpers, JMA van Gerven, TL Beumer
EUROPEAN JOURNAL OF NEUROLOGY 17, 493-493, 2010
12010
Pharmacologic resting state-FMRI: effects of cannabis on functional brain connectivity at rest
RP Soeter, LE Klumpers, N Khalili-Mahani, MA van Buchem, ...
Annual Meeting of the Organization for Human Brain Mapping, Barcelona, Spain, 2010
12010
Tolerability of High-Dose Oral Δ9-THC: Implications for Human Laboratory Study Design
J Rozanc, LE Klumpers, MA Huestis, M Tagen
Cannabis and Cannabinoid Research, 2024
2024
Pharmacokinetics of Two Nanoemulsion Formulations of Δ8-Tetrahydrocannabinol in Rats
M Tagen, LE Klumpers, A Peshkovsky
AAPS PharmSciTech 24 (8), 239, 2023
2023
380 Prediction of a Therapeutically Active Dose of the Cannabinoid Type 1 Receptor Antagonist ANEB-001 for Reversal of Acute Cannabis Intoxication Using a Pharmacokinetic …
L Klumpers, A Gorbenko, J Heuberger, K Cundy, GJ Groeneveld, ...
Annals of Emergency Medicine 82 (4), S167, 2023
2023
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20